Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018

  • ID: 4479929
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Emergent BioSolutions Inc
  • GeoVax Labs Inc
  • Johnson & Johnson
  • NanoViricides Inc
  • Phoenix Biotechnology Inc
  • MORE
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Emergent BioSolutions Inc
  • GeoVax Labs Inc
  • Johnson & Johnson
  • NanoViricides Inc
  • Phoenix Biotechnology Inc
  • MORE
Introduction

Report Coverage

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development

BioCryst Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

GeoVax Labs Inc

Integrated BioTherapeutics Inc

Johnson & Johnson

NanoViricides Inc

Phoenix Biotechnology Inc

Profectus BioSciences Inc

Rodos BioTarget GmbH

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles

(Ebola + Marburg) (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

1-E703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies for Ebola and Marburg Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eritoran tetrasodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galidesivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOEM-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GreEMTri - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-191N - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-78 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-05204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-69120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones

Featured News & Press Releases

Jan 10, 2018 : TSRI scientists discover workings of first promising Marburg virus treatment

Sep 28, 2017: New Research Indicates Expanded Potential Uses For Phoenix Biotech Drug PBI-05204: Inhibits Ebola and Marburg Viruses and Offers Novel Treatment Approaches For Alzheimer's and Parkinson's Diseases

Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus

Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates

Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract

Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies

Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory

Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

Oct 31, 2014: Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates

Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

Jul 31, 2014: UTMB researchers receive over $6 million to develop treatment for deadly Ebola and Marburg viruses

Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease

May 05, 2011: IBT Receives NIAID Advanced Technology Phase I SBIR Grant

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Phoenix Biotechnology Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H1 2018

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioCryst Pharmaceuticals Inc
  • Eisai Co Ltd
  • Emergent BioSolutions Inc
  • GeoVax Labs Inc
  • Integrated BioTherapeutics Inc
  • Johnson & Johnson
  • NanoViricides Inc
  • Phoenix Biotechnology Inc
  • Profectus BioSciences Inc
  • Rodos BioTarget GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll